We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

148 hedge funds and large institutions have $317M invested in Progenics Pharmaceuticals Inc in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 36 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 36

2% more capital invested

Capital invested by funds: $311M → $317M (+$6.6M)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

1% less funds holding

Funds holding: 150 → 148 (-2)

32% less call options, than puts

Call options by funds: $612K | Put options by funds: $896K

Holders
148
Holders Change
-2
Holders Change %
-1.33%
% of All Funds
3.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
62
Reduced
36
Closed
19
Calls
$612K
Puts
$896K
Net Calls
-$284K
Net Calls Change
-$236K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$6.97M
2
Deutsche Bank
Deutsche Bank
Germany
+$5.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.64M
4
AAP
Ardsley Advisory Partners
Connecticut
+$3.29M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.84M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$23.9M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$14.5M
3
Citadel Advisors
Citadel Advisors
Florida
-$5M
4
PFC
Phocas Financial Corp
California
-$2.5M
5
Citigroup
Citigroup
New York
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
JG
101
Jefferies Group
New York
$89K +$86.4K +19,100 New
Man Group
102
Man Group
United Kingdom
$88K +$86K +19,000 New
Creative Planning
103
Creative Planning
Kansas
$83K – – –
BNP Paribas Financial Markets
104
BNP Paribas Financial Markets
France
$81.5K +$79.3K +17,529 +64,922%
TRSOTSOK
105
Teachers Retirement System of the State of Kentucky
Kentucky
$81K – – –
VF
106
Virtu Financial
New York
$79K +$77.4K +17,101 New
Fifth Third Bancorp
107
Fifth Third Bancorp
Ohio
$73K – – –
AB
108
Amalgamated Bank
New York
$60K +$1.63K +360 +3%
DSC
109
Duncker Streett & Co
Missouri
$59K – – –
LPL Financial
110
LPL Financial
California
$56K +$5.56K +1,228 +11%
HF
111
HRT Financial
New York
$56K +$55.2K +12,209 New
AG
112
Advisor Group
Arizona
$53K -$6.43K -1,422 -11%
USAA
113
United Services Automobile Association
Texas
$51K – – –
TA
114
Teton Advisors
New York
$46K – – –
QT
115
Quantamental Technologies
New York
$44K -$2.71K -600 -6%
AIP
116
Ameritas Investment Partners
Nebraska
$27K – – –
SEI Investments
117
SEI Investments
Pennsylvania
$26K -$90.7K -20,043 -77%
Simplex Trading
118
Simplex Trading
Illinois
$26K +$25.4K +5,618 New
CHP
119
Cable Hill Partners
Oregon
$22K – – –
Zurich Cantonal Bank
120
Zurich Cantonal Bank
Switzerland
$22K – – –
PNC Financial Services Group
121
PNC Financial Services Group
Pennsylvania
$18K +$1.58K +350 +10%
MCM
122
Manchester Capital Management
Vermont
$14K +$13.7K +3,020 New
LIA
123
LS Investment Advisors
Michigan
$11K – – –
MOACM
124
Mutual of America Capital Management
New York
$11K +$1.45K +320 +15%
Bank of Montreal
125
Bank of Montreal
Ontario, Canada
$11K +$4.92K +1,088 +91%
3 4
5
6 7

PGNX Hedge Fund Activity: Q1 2019 in Review

148 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2019, worth a combined $317M — up 2.1% from $311M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PGNX and 18 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 62 added.

The largest buyer was Vanguard Group, adding an estimated $6.97M. The largest seller was Armistice Capital, exiting entirely with an estimated $23.9M sold.

  • 148 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2019, down from 150 in Q4 2018.
  • Funds reported $317M of Progenics Pharmaceuticals Inc stock for Q1 2019, up 2.1% quarter-over-quarter.
  • 18 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2019 and 19 closed out, a net change of -1 holder.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2019 was Vanguard Group, an estimated $6.97M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2019 was Armistice Capital, an estimated $23.9M sold.

Based on aggregated 13F filings for Q1 2019.